SM
REGN icon

Sabby Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Sabby Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-162,517
Closed -$59.7M – 303
2016
Q4 		$59.7M Buy
162,517
+86,598
+114% +$32.9M 3.47% 6
2016
Q3 		$30.5M Buy
75,919
+4,394
+6% +$1.76M 1.14% 15
2016
Q2 		$25M Buy
71,525
+32,498
+83% +$12.5M 1.3% 16
2016
Q1 		$14.1M Buy
+39,027
New +$16.1M 0.7% 23
2015
Q4 		– Sell
-1,150
Closed -$535K – 359
2015
Q3 		$535K Buy
+1,150
New +$618K 0.02% 288
2014
Q3 		– Sell
-48,177
Closed -$16.1M – 287
2014
Q2 		$13.6M Buy
48,177
+30,986
+180% +$9.18M 0.58% 31
2014
Q1 		$5.16M Buy
+17,191
New +$5.3M 0.29% 63

Other funds holding REGN

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return
Polen Capital Management
Polen Capital Management Boca Raton, Florida $11.6B AUM 8.03% 1-Year Est. Return

Sabby Management's REGN Position: Q1 2017 in Review

Sabby Management sold out of Regeneron Pharmaceuticals (REGN) in Q1 2017, closing a stake of 162,517 shares — an estimated $59.7M sold.

Sabby Management first reported a position in REGN in Q1 2014 and held it in 7 quarters. The position peaked at $59.7M in Q4 2016. 579 funds tracked by Wall St. Rank hold REGN as of Q1 2017.

  • Sabby Management reported no remaining Regeneron Pharmaceuticals position as of Q1 2017 after selling out during the quarter.
  • Sabby Management sold 162,517 Regeneron Pharmaceuticals shares in Q1 2017, an estimated $59.7M.
  • Sabby Management first reported a position in Regeneron Pharmaceuticals in Q1 2014 and held it in 7 quarters.
  • Sabby Management's Regeneron Pharmaceuticals position peaked at $59.7M in Q4 2016.
  • 579 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2017.

Based on Sabby Management's 13F filing for Q1 2017, filed 15 May 2017.